Skip to search formSkip to main contentSkip to account menu

beractant

Known as: beractant [Chemical/Ingredient], surfactant-TA 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (2)

Biological ProductsPulmonary Surfactants
Drug AllergyPreterm InfantRespiratory Distress Syndrome, NewbornSurfactant Activity [MoA]

Narrower (1)

Survanta

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Medication Use in the Neonatal Intensive Care Unit
Abstract Objective The aim of the article is to provide an update on medication use in infants admitted to the neonatal intensive… 
Highly Cited
2011
Highly Cited
2011
Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study
Objective:The objective of this study is to compare all-cause in-hospital mortality in preterm infants with respiratory distress… 
2010
2010
Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome
Objective:Comparison of the differences between availability of animal-derived surfactant preparations used to treat premature… 
Highly Cited
2005
Highly Cited
2005
A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants
Background and Objective. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through… 
Review
2005
Review
2005
History of Surfactant from 1980
The first successful trial of surfactant treatment for respiratory distress syndrome (RDS) was reported in 1980. Since then there… 
2001
2001
Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease
The aim of this study was to demonstrate that administration of the second dose of beractant 2 h after the first one is more… 
Highly Cited
2000
Highly Cited
2000
Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization.
OBJECTIVE Over the last decade, several new therapies, including high-frequency oscillatory ventilation (HFOV), exogenous… 
Highly Cited
1998
Highly Cited
1998
Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group.
Highly Cited
1997
Highly Cited
1997
Exogenous surfactant enhances the delivery of recombinant adenoviral vectors to the lung.
Somatic gene therapy for pulmonary diseases must be accomplished in vivo, requiring the spread of a gene transfer vector across a… 
Highly Cited
1996
Highly Cited
1996
Comparative Effects of Some Serum Components and Proteolytic Products of Fibrinogen on Surface Tension-Lowering Abilities of Beractant and a Synthetic Peptide Containing Surfactant KL41
The serum components of C-reactive protein, lysophosphatidylcholine, fibrinogen, and fibrinogen proteolytic products have been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)